Tandem Diabetes Care delivered one of the week's more dramatic squeeze setups — a heavily shorted stock that jumped 19% in a single session after earnings, leaving nearly 19% of the float still betting against it.
The catalyst was Wednesday's Q2 print. The stock closed at $22.39 on Friday, up 15% on the week and 45% over the past month. That kind of velocity matters when 12.8 million shares — roughly 19% of the free float — remain short. Shorts who built positions through July at prices well below current levels are now sitting on significant mark-to-market pain, and the week's data shows early signs of covering: short interest has eased roughly 1% in both the one-day and one-week windows, though it remains 17% above where it sat a month ago. The stock has moved sharply faster than short interest has unwound.
The borrow market tells a story of two distinct dynamics. Despite the elevated short interest, availability is genuinely loose — nearly 900% on the latest reading, well above the 52-week low of 290%, meaning there are roughly nine shares available to borrow for every one already lent out. Cost to borrow is low at 0.52%, roughly where it has been for weeks. That combination — high short interest, high availability, cheap borrow — suggests the shorts are not being squeezed out of the lending market. They can hold their positions. The question is whether they choose to. Options positioning has shifted notably since the earnings pop: the put/call ratio jumped to 0.72 on Friday, more than two standard deviations above its 20-day average of 0.44. That is the most defensive options setup TNDM has seen in months, and the flip happened abruptly — as recently as August 3rd the PCR was 0.33. Some market participants are now paying up for downside protection at the new, higher price level.
Analyst reaction to the earnings beat has been characteristically split. Citigroup lifted its target from $17 to $21 while keeping a Neutral rating — still below the current price of $22.39. RBC Capital moved in the opposite direction, trimming its Outperform target from $30 to $26. The Street consensus target is $28.30, implying roughly 26% upside from here, but several firms have spent the past three months cutting targets: UBS took its number from $22 to $18 just two weeks ago, Mizuho cut from $24 to $20 in mid-July, and Bank of America trimmed from $35 to $25 in May. Deutsche Bank initiated in late June at a Hold with a $15.50 target — a number the stock has now blown well through. The bull case rests on pharmacy channel conversion, which management has framed as a multi-year margin expansion opportunity. The bear case is that the conversion timeline is aggressive and competition in insulin delivery remains fierce. With EV/EBITDA at 15.5x and the PE deeply negative, the stock is trading entirely on the execution story rather than current earnings power.
The ORTEX short score has edged down slightly from 59.3 earlier in the week to 57.9 — still elevated but not at an extreme, and the direction of travel is modestly lower as the post-earnings relief reduces some of the bearish signal intensity. The short score factor rank places TNDM in the bottom quartile at 14, meaning the positioning is still skewed significantly against the stock relative to the broader universe. Peer PODD fell 15% on the week — a notable divergence from TNDM's 15% gain — suggesting this week's move was company-specific rather than a sector-wide re-rating.
What to watch next: the rate at which short interest unwinds from the 19% level will define whether this is a genuine re-rating or a relief rally that gives shorts a better entry — and the next scheduled earnings event is not until November 4, leaving several months of positioning drift with no hard catalyst on the horizon.
See the live data behind this article on ORTEX.
Open TNDM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
